Abstract:Rapid developments in Regenerative Medicine and Tissue Engineering has witnessed an increasing drive toward clinical translation of breakthrough technologies. However, the progression of promising preclinical data to achieve successful clinical market authorisation remains a bottleneck. One hurdle for progress to the clinic is the transition from small animal research to advanced preclinical studies in large animals to test safety and efficacy of products. Notwithstanding this, to draw meaningful and reliable conclusions from animal experiments it is critical that the species and disease model of choice is relevant to answer the research question as well as the clinical problem. Selecting the most appropriate animal model requires in-depth knowledge of specific species and breeds to ascertain the adequacy of the model and outcome measures that closely mirror the clinical situation. Traditional reductionist approaches in animal experiments, which often do not sufficiently reflect the studied disease, are still the norm and can result in a disconnect in outcomes observed between animal studies and clinical trials. To address these concerns a reconsideration in approach will be required. This should include a stepwise approach using in vitro and ex vivo experiments as well as in silico modeling to minimize the need for in vivo studies for screening and early development studies, followed by large animal models which more closely resemble human disease. Naturally occurring, or spontaneous diseases in large animals remain a largely untapped resource, and given the similarities in pathophysiology to humans they not only allow for studying new treatment strategies but also disease etiology and prevention. Naturally occurring disease models, particularly for longer lived large animal species, allow for studying disorders at an age when the disease is most prevalent. As these diseases are usually also a concern in the chosen veterinary species they would be beneficiaries of newly developed therapies. Improved awareness of the progress in animal models is mutually beneficial for animals, researchers, human and veterinary patients. In this overview we describe advantages and disadvantages of various animal models including domesticated and companion animals used in regenerative medicine and tissue engineering to provide an informed choice of disease-relevant animal models.

Animal Models for Heart Transplantation Focusing on the Pathological Conditions

Small Mammalian Animal Models of Heart Disease.

Large Mammalian Animal Models of Heart Disease

Introduction of Modified Cervical Cardiac Transplant Model in Mice.

Mouse Heterotopic Abdominal Heart Transplant Model

Animal Models of Cardiac Disease and Stem Cell Therapy.

Animal models for partial heart transplantation

Animal models for transplant immunology: bridging bench to bedside

Animal Models for Cardiovascular Research

Animal models in xenotransplantation

Preclinical Large Animal Porcine Models for Cardiac Regeneration and Its Clinical Translation: Role of hiPSC-Derived Cardiomyocytes

Research('s) Sweet Hearts: Experimental Biomedical Models of Diabetic Cardiomyopathy

Heart Xenotransplantation in Primate Models

A Modified Murine Heterotopic Heart Transplant Protocol Matching Contemporary Standards of Aseptic Technique, Anesthesia, and Analgesia

Small and large animal models in cardiac contraction research: advantages and disadvantages

Organ Transplantation in Rodents: Novel Applications of Long-Established Methods

Molecular Imaging of Acute Cardiac Transplant Rejection: Animal Experiments and Prospects.

Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do

A Standardized Approach to Orthotopic (Life-Supporting) Porcine Cardiac Xenotransplantation in a Non-Human Primate Model

Animal Models of Ischemic Heart Disease for in Vivo Cardiac MR Imaging Research

Preclinical Animal Models in Facial Transplantation